Core Viewpoint - Salarius Pharmaceuticals has adjourned its 2025 Annual Meeting of Stockholders to solicit additional votes due to insufficient quorum, with the meeting reconvened for December 31, 2025 [1][2]. Company Information - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatment options for cancer patients, with two drug candidates in its portfolio: seclidemstat and SP-3164 [9]. - Seclidemstat is being studied in a Phase 1/2 clinical trial for hematologic cancers at MD Anderson Cancer Center, targeting myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [9]. - SP-3164 is an oral small molecule protein degrader currently in the IND stage [9]. - The company has received financial support for its drug candidates from various organizations, including the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas [9]. Meeting Details - The required quorum for the Annual Meeting is 34% of outstanding shares, but only approximately 30% of shares were represented at the time of adjournment [2][3]. - Stockholders eligible to vote are encouraged to do so via the Internet or phone, with the record date for voting remaining October 24, 2025 [3][4]. - The reconvened meeting will be held virtually, allowing stockholders to participate online [2]. Subsidiary Information - Salarius' subsidiary, Decoy Therapeutics Inc., is a preclinical-stage biotechnology company utilizing machine learning and AI tools to develop peptide conjugate drug candidates targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [7]. - Decoy has secured financing from institutional investors and various funding programs, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [7].

Core Insights - Cloud computing is increasingly vital for innovation and digital transformation, allowing users to access and store data over the Internet without managing physical servers [2] - Major tech firms like Microsoft, Alphabet, Amazon, and IBM are essential for investment portfolios focused on cloud computing [3] Industry Overview - The global cloud computing market is projected to grow from $752.4 billion in 2024 to $2,390.2 billion by 2030, reflecting a CAGR of 20.4% [6] - Cloud computing services are categorized into IaaS, PaaS, serverless, and SaaS, providing various control and management options for enterprises [5] Company Insights Microsoft - Microsoft Azure offers a wide range of IaaS and PaaS solutions, enhancing its competitive position with increased availability in over 60 regions globally [9][10] - The company is heavily investing in AI-powered cloud services, integrating technologies like Azure OpenAI Service and Copilot [12] Alphabet - Google Cloud has become a key growth driver for Alphabet, expanding its cloud footprint with 42 cloud regions and 127 availability zones [14] - The company's investments in AI and cloud computing are expected to bolster its long-term prospects despite competitive pressures [15] Amazon - Amazon Web Services (AWS) is a leading player in the IaaS market, offering over 200 services and catering to a diverse customer base [16][17] - AWS aims to enhance its AI and ML capabilities while expanding its global infrastructure for improved service delivery [18] IBM - IBM has strengthened its position in the hybrid cloud market through the acquisition of Red Hat, which enhances its cloud and data platform offerings [19] - The company is well-positioned to benefit from the growing demand for hybrid cloud and AI solutions, driving growth in its Software and Consulting segments [21]

Core Insights - NextNRG, Inc. is set to achieve record fuel volumes in Q4 2025, driven by strong holiday demand and effective operational execution [1] Delivery Performance - In Q3 2025, NextNRG delivered approximately 6.5 million gallons, a significant increase from about 1.9 million gallons in Q3 2024 [2] - December 2025 deliveries are projected to reach around 2.5 million gallons, compared to approximately 620,000 gallons in December 2024 [2] - The company anticipates delivering approximately 7.0 million gallons in Q4 2025, marking the highest quarterly fuel volume in its history [3] Operational Efficiency - NextNRG's mobile fueling platform enhances fleet efficiency by providing on-site fueling solutions, reducing downtime during peak demand periods [4] - The company emphasizes operational discipline, customer retention, fleet expansion, and route optimization to capture growing market demand [5] Future Outlook - NextNRG expects to maintain operational momentum into 2026 through ongoing optimization and improved routing efficiency [6] Company Overview - NextNRG integrates AI and machine learning into energy management, focusing on utility infrastructure, battery storage, and mobile fuel delivery [7] - The Next Utility Operating System® optimizes infrastructure across microgrids and fleet operations, contributing to cost savings and decarbonization [8]

Generative vs. discriminative models in ML:(a popular ML interview question) https://t.co/r3c5l3NIDx ...

Core Insights - The article emphasizes the importance of high-precision network planning and simulation in the context of industrial internet and smart manufacturing, highlighting the unique value of Ranplan Professional and Ranplan Academic in both industry and academia [1][5]. Group 1: Ranplan Professional - Ranplan Professional is an advanced 3D modeling and network simulation platform designed for communication operators, equipment manufacturers, and vertical industries such as smart manufacturing and smart mining [1]. - The platform provides full lifecycle network support from design to optimization, significantly reducing investment risks and post-deployment rectification costs through high-precision digital twins [1][5]. - In a case study involving smart LNG ship wireless network planning, the platform achieved a coverage compliance rate of 99% while reducing construction costs by 30% [4]. - In a smart mining 5G private network optimization project, the platform improved coverage while successfully reducing the number of base station antennas, achieving both efficiency and cost optimization [4]. Group 2: Ranplan Academic - Ranplan Academic is tailored for universities and research institutions, inheriting the core simulation engine and modeling capabilities of the Professional version [1][5]. - The software features a high-precision 3D ray-tracing simulation engine that can predict signal behavior in complex environments with an error margin of less than 5 dB, covering a frequency range from 100 MHz to 70 GHz [1][5]. - It supports various engineering data formats for detailed 3D modeling, enabling accurate simulations in environments with complex layouts [1][5]. - The platform integrates intelligent algorithms for automatic optimization of network parameters, helping enterprises save approximately 20% to 30% on network rectification and maintenance costs [1][5]. - It supports the simulation of multiple network standards and advanced technologies, providing a validation platform for future network evolution [1][5]. Group 3: Industry Empowerment - Ranplan offers a comprehensive solution centered on high-precision digital twins and professional wireless communication knowledge, directly serving industries like manufacturing, energy, and transportation in their digital transformation [5]. - The company has invested nearly 500 million yuan over more than a decade in research and development, establishing significant technological advantages in the niche of wireless network planning and simulation [5]. - The platforms are positioned as valuable tools for users seeking reliability in network planning, forward-looking research capabilities, or professional talent cultivation [5].

Industry Overview - The global oncology market is evolving significantly due to rising cancer incidence and rapid scientific advancements, with the American Cancer Society estimating approximately 2.04 million new cancer diagnoses and over 618,000 cancer-related deaths in the U.S. by 2025 [2] - Aging populations and lifestyle-related risk factors are contributing to higher cancer prevalence, leading to sustained growth in healthcare spending on oncology [2] Innovation in Cancer Care - Breakthroughs in immunotherapies, targeted treatments, and personalized vaccines are expanding therapeutic options beyond conventional chemotherapy and radiation [3] - Immune-based strategies, including checkpoint inhibitors and CAR-T therapies, are harnessing the body's immune system to target tumors, while targeted therapies focus on specific genetic alterations [3] - Emerging technologies like genomic sequencing, AI, and machine learning are enhancing biomarker discovery and supporting earlier diagnosis, improving survival rates and quality of life across several cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, Johnson & Johnson (J&J), Pfizer, AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly, are investing aggressively in oncology portfolios with new therapies such as antibody-drug conjugates and bispecific antibodies [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing agreements, and acquisitions [5] Market Dynamics - Oncology is considered one of the most durable and attractive segments within the global healthcare sector for long-term investors, supported by ongoing innovation and favorable reimbursement dynamics [6] Company Focus: Johnson & Johnson - J&J's oncology segment currently accounts for approximately 27% of its total revenues, with oncology sales rising 20.6% to $18.52 billion in the first nine months, driven by key products like Darzalex and Erleada [9] - J&J's oncology pipeline has gained momentum with promising developments in colorectal and head and neck cancers, and the company expects its oncology sales to reach $50 billion by the end of the decade [10][12] - J&J is also enhancing its oncology pipeline through M&A, including a recent agreement to acquire Halda Therapeutics [11] Company Focus: ImmunityBio - ImmunityBio's lead drug, Anktiva, was approved for treating BCG-unresponsive non-muscle invasive bladder cancer, generating $74.7 million in sales with a 467% increase in volume [13] - The drug is under review in the EU, and ImmunityBio is evaluating Anktiva for expanded use in other cancer indications [15] Company Focus: Foghorn Therapeutics - Foghorn Therapeutics is developing precision therapies targeting genetically driven vulnerabilities, with a collaboration with Lilly to co-develop its selective SMARCA2 oncology program [17] - Foghorn's lead candidate, FHD-909, is advancing in a phase I study for SMARCA4-mutated cancers, with initial data expected in 2026 [17][18]

Core Insights - NetraMark Holdings Inc. has made significant progress in commercial execution, regulatory engagement, and scientific validation, strengthening its growth trajectory in AI-driven clinical trial optimization [1][2] Group 1: Contract Backlog and Financial Outlook - The contract backlog for NetraMark increased to approximately C$2.5 million, driven by new project commitments and commercial momentum, with a target of reaching C$8–$10 million by mid-2026 [2][4] - The company is experiencing growing commercial traction and expanding channel partnerships, which support its financial outlook [4] Group 2: Regulatory Engagement - NetraMark completed a Critical Path Innovation Meeting (CPIM) with the FDA, receiving feedback on its NetraAI platform and its application in clinical trial design [2] - The FDA discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, aligning with FDA enrichment guidance [2] Group 3: Scientific Validation - A scientific study on NetraAI was accepted for publication in npj Digital Medicine, demonstrating its ability to identify clinically meaningful subgroups in a Phase II depression trial [2] - The acceptance by a high-impact journal provides third-party validation of NetraMark's scientific approach [2] Group 4: Strategic Collaborations - NetraMark secured an Ontario Research Fund – Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH), focusing on analyzing genetic and epigenetic data in psychiatric disorders [2] - This collaboration aims to enhance NetraAI's capabilities in identifying explainable patient subpopulations [2]

Core Viewpoint - Azitra, Inc. has received approval from NYSE American for its compliance plan to meet continued listing standards after previously being notified of non-compliance due to insufficient stockholders' equity [1][2]. Group 1: Compliance and Listing Status - Azitra must regain compliance with the NYSE American listing standards by April 1, 2027, or face potential delisting proceedings [2]. - The company will remain listed on NYSE American during the compliance plan period and will undergo periodic reviews, including quarterly monitoring [3]. - Receipt of the notice from the Exchange does not immediately affect the listing or trading of Azitra's common stock [4]. Group 2: Company Overview and Programs - Azitra is a clinical stage biopharmaceutical company focused on precision dermatology, with its lead program ATR-12 targeting Netherton syndrome, a rare skin disease [5]. - The ATR-12 program includes a Phase 1b clinical trial in adult patients, while the ATR-04 program addresses EGFR inhibitor-associated rash and has received Fast Track designation from the FDA [5]. - Azitra's proprietary platform includes a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning for drug development [5].

Industry Overview - The global payments industry is experiencing a positive growth environment, driven by the transition to digital and electronic payment methods, with consumer spending continuing to grow [2] - The U.S. central bank has lowered interest rates three times in 2025, which supports consumer spending and improves credit conditions, potentially boosting payment volumes [3][4] - Companies in the payment industry are pursuing mergers and acquisitions to diversify their revenue streams and stabilize their top line [5] Growth Drivers - The quality of growth in the payments space is improving, with revenues increasingly driven by value-added services such as fraud prevention and data analytics [6] - Continued innovation and enhanced security in transactions are expected to benefit payment companies [7] - Real-time and account-to-account payments are gaining traction, increasing overall transaction frequency and creating a favorable backdrop for payment stocks [8] Company Highlights - **Capital One Financial Corp. (COF)**: Expected to benefit from growing consumer loan demand, solid credit card operations, and opportunistic buyouts, with a projected earnings growth of 1.5% and revenue growth of 17.4% for 2026 [10][11][12] - **OppFi Inc. (OPFI)**: Focus on AI and machine learning is expected to improve operating efficiency and support margin expansion, with projected earnings growth of 8.6% and revenue growth of 9.1% for 2026 [13][14] - **SoFi Technologies, Inc. (SOFI)**: Innovation and an expanding digital financial ecosystem are expected to drive growth, with projected earnings growth of 62.9% and revenue growth of 25.4% for 2026 [15][16]

In 2023, Kalyani Ramadurgam founded Kobalt Labs with former Affirm software engineer Ashi Agrawal to bring compliance into the machine-learning age. Kobalt's AI models sort through mountains of documents to help banks vet their business partners, ensuring they're following the rules, like halting money transfers from sanctioned countries and promptly disclosing security breaches. #ForbesUnder30Read more: https://t.co/Pq2lx0UdZgPhoto: Sebastian Nevols for Forbes ...